# THE AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS (AXIS) STUDY

**The AXIS study** is a prospective cross-sectional study that has been conducted under the umbrella of **ASAS** and **GRAPPA**.

**The overarching aim** of the AXIS study is to systematically evaluate clinical and imaging manifestations indicative of axial involvement (based on local and central assessments) in patients with PsA to develop classification criteria and a unified nomenclature for axial involvement in PsA that would allow defining a homogeneous subgroup of patients for research.

Study Population includes:

- consecutive patients diagnosed with PsA,
- fulfilling the CASPAR classification criteria,
- symptom duration of up to 10 years,
- b- or ts- DMARDs naïve

We are pleased to announce with you some significant milestones achieved in the AXIS study. To date, 362 patients have been enrolled across all participating centers. Furthermore, the electronic Case Report Forms (eCRFs) for 304 patients have been successfully completed and submitted. A total of 250 patients' images have been centrally reviewed, and central clinical reviews of 208 patients have been completed.



In total 11 centers have reached the maximum number of inclusions either due to reaching the maximum per center or per country. These centers are Chapel Allerton Hospital - Leeds Teaching Hospitals NHS Trust (UK), Bradford Hospitals Foundation NHS Trust (UK), Derby Queen's Hospital and Burton NHS Foundation Trust (UK), Cambridge University Hospitals (UK), The Royal Bournemouth & Christchurch Hospital NHS Foundation Trust (UK), Derby F. Nightingale Hospital (UK), Rheumazentrum Ruhrgebiet-Herne (DE), Charité - Universitätsmedizin Berlin (DE), Westville Hospital, Durban (ZA), Chung Shan Medical University hospital (TW), and Seattle Rheumatology Associates (USA).
Please kindly find on the next page an overview about included patients in the AXIS study.

Given the competitive nature of patient participation on a first-come, first-served basis with maximum quotas per center and country, we remind you of the following important points regarding enrollment:



**Data Completeness:** Please ensure that all required information in the eCRFs is complete and that all imaging has been uploaded for each patient you have enrolled.

**Timely Submission:** If you have patients with completed clinical data and images, please sign and submit their eCRFs as promptly as possible.

**Pending Entries:** For patients whose clinical visits and imaging studies are complete but have not yet been entered into the eCRF, please do so at your earliest convenience.

**Note on Over-Enrollment**: To prevent over-enrollment, we strongly recommend contacting the study coordinator prior to adding more patients to the eCRF or scheduling additional patient visits.

**We extend our deepest gratitude to all participating centers and researchers for your invaluable collaboration and tireless efforts in moving this study forward.**


Overview Per Country
Brazil
Lebanon
Canada
Mexico
Romania
Turkey
Argentina
Singapore
India
Hong Kong
South Africa
Taiwan
Spain
USA
Italy
Germany
U.Kingdom
0
5
10
15
20
25
30
35
40
45
50
Central Clinical Review
Central Imaging Review
eCRF Completed
Inclusions